Adaptimmune therapeutics plc (ADAP)
Balance Sheet / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Jun'15Jun'14
Assets
Current assets
Cash and cash equivalents

86,429

50,412

39,409

34,574

49,917

68,379

153,081

42,312

53,375

84,043

145,326

121,998

170,559

158,779

140,440

150,894

163,766

194,263

229,046

51,179

Short-term deposits

-

-

-

-

-

-

-

-

-

-

-

18,000

33,114

22,694

47,064

55,031

62,337

54,620

55,292

-

Marketable securities - available-for-sale debt securities

110,000

39,130

63,451

98,832

118,241

136,755

84,652

86,716

108,459

124,218

86,532

80,023

-

-

-

-

-

-

-

-

Accounts receivable, net of allowance for doubtful accounts of $0 and $0

-

-

-

3,809

-

192

2,031

-

5,052

206

4,063

1,406

107

1,480

-

-

1

744

4

138

Other current assets and prepaid expenses (including current portion of clinical materials)

31,332

30,947

44,110

37,918

32,143

25,769

21,841

32,626

28,777

21,716

17,983

16,317

19,152

15,798

12,040

12,257

12,457

13,420

10,740

2,990

Total current assets

227,761

120,489

146,970

175,133

200,301

231,095

261,605

161,654

195,663

230,183

253,904

237,744

222,932

198,751

199,544

218,182

238,561

263,047

295,082

54,307

Restricted cash

4,331

4,496

4,318

4,403

4,473

4,097

4,163

4,195

4,360

4,253

4,232

4,156

4,049

4,017

4,146

4,229

4,413

4,508

-

-

Clinical materials

2,611

2,503

2,485

2,690

3,972

3,953

4,205

4,782

4,572

4,695

2,096

2,026

2,597

2,580

2,741

2,695

3,601

4,736

-

-

Operating lease right-of-use assets, net of accumulated amortization

19,498

20,789

20,563

21,507

24,462

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Property, plant and equipment, net of accumulated depreciation of $24,274 (2019: $23,649)

28,674

31,068

31,641

33,722

35,703

36,118

38,137

39,472

41,235

40,679

39,771

38,922

35,092

27,899

15,086

13,444

13,845

13,225

5,393

1,428

Intangibles, net of accumulated amortization

2,366

2,198

2,274

2,066

1,529

1,473

1,515

1,196

1,238

1,337

1,374

1,431

1,310

1,268

1,127

1,010

1,140

305

178

-

Deferred revenue

-

-

-

-

-

-

-

-

-

38,735

42,592

12,304

11,625

11,392

9,514

9,940

12,077

12,487

20,906

41,790

Total assets

285,241

181,543

208,251

239,521

270,440

276,736

309,625

211,299

247,068

281,147

301,377

284,279

265,980

234,515

222,644

239,560

261,560

285,821

300,653

55,735

Liabilities and stockholders' equity
Current liabilities
Accounts payable

7,066

6,357

5,535

4,344

5,391

4,083

3,907

4,131

5,051

8,378

2,489

4,577

5,177

11,350

3,193

2,474

2,440

7,884

1,982

1,010

Operating lease liabilities, current

2,590

2,493

2,337

2,338

2,217

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued expenses and other accrued liabilities

18,502

23,363

26,846

18,595

15,827

20,354

24,314

21,457

19,650

27,201

23,491

13,372

15,110

17,528

9,954

7,723

5,321

7,518

3,877

9,978

Deferred revenue, current

1,658

2,128

2,683

3,016

-

-

1,345

16,722

27,221

-

-

-

-

-

-

-

-

-

-

-

Total current liabilities

29,816

34,341

37,401

28,293

23,435

24,437

29,566

42,310

51,922

74,314

68,572

30,253

31,912

40,270

22,661

20,137

19,838

27,889

26,765

52,778

Operating lease liabilities, non-current

21,829

22,966

22,599

23,666

26,779

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue, non-current

46,974

-

-

-

-

-

-

-

-

-

-

20,754

22,394

24,962

19,335

22,432

22,776

22,939

14,885

-

Other liabilities, non-current

585

598

568

571

571

5,414

3,904

3,887

3,884

3,849

3,820

3,777

3,348

3,141

644

-

-

-

-

-

Total liabilities

99,204

57,905

60,568

52,530

50,785

29,851

33,470

46,197

55,806

78,163

72,392

54,784

57,654

68,373

42,640

42,569

42,614

50,828

41,650

52,778

Contingencies and commitments - Note 9

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

Stockholders' equity
Common stock - Ordinary shares par value 0.001, 785,857,300 authorized and 780,514,340 issued and outstanding (2019: 785,857,300 authorized and 631,003,568 issued and outstanding)

1,139

943

943

943

940

939

939

860

858

854

854

853

801

683

682

682

682

682

682

291

Additional paid in capital

678,319

585,623

583,065

581,245

577,722

574,208

570,355

466,229

461,603

455,401

452,553

448,985

405,165

341,200

339,188

336,904

334,437

332,363

328,795

32,512

Accumulated other comprehensive loss

-9,590

-7,264

-10,025

-8,199

-13,096

-9,763

-12,813

-14,419

-27,136

-21,641

-20,055

-16,854

-14,366

-14,249

-13,788

-13,011

-10,684

-8,139

-3,561

274

Accumulated deficit

-483,800

-455,664

-426,300

-387,000

-345,911

-318,499

-282,326

-287,568

-244,063

-231,630

-204,367

-203,489

-183,274

-161,492

-146,078

-127,584

-105,489

-89,913

-66,913

-30,120

Total stockholders' equity

186,037

123,638

147,683

186,991

219,655

246,885

276,155

165,102

191,262

202,984

228,985

229,495

208,326

166,142

180,004

196,991

218,946

234,993

259,003

2,957

Total liabilities and stockholders' equity

285,241

181,543

208,251

239,521

270,440

276,736

309,625

211,299

247,068

281,147

301,377

284,279

265,980

234,515

222,644

239,560

261,560

285,821

300,653

55,735